+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity



Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity



British Journal of Cancer 78(3): 336-343



DMXAA (5.6-dimethylxanthenone-4-acetic acid), a novel anti-tumour agent currently undergoing clinical evaluation, appears to mediate its anti-tumour effects through immune modulation and the production of the cytokine tumour necrosis factor-alpha (TNF). Our previous studies have shown that thalidomide, a potent inhibitor of TNF biosynthesis that has numerous biological effects, including inhibition of tumour angiogenesis, unexpectedly augments the anti-tumour response in mice to DMXAA. We show here that thalidomide (100 mg kg-1) has no effect when administered with inactive doses of DMXAA, and that it must be given simultaneously With an active dose of DMXAA to have its maximum potentiating effect on the growth of the murine Colon 38 adenocarcinoma. To address the issue of whether inhibition of serum TNF production is important for potentiation of anti-tumour activity, we have tested three potent analogues of thalidomide. All three analogues, when co-administered with DMXAA to mice at doses lower than those used with thalidomide, inhibited TNF production and were effective in potentiating the anti-tumour activity of DMXAA against transplanted Colon 38 tumours. One of the analogues, N-phenethyltetrafluorophthalimide, was 1 000-fold more potent than thalidomide and at a dose of 0.1 mg kg-1 in combination with DMXAA (30 mg kg-1) cured 100% of mice, compared with 67% for the group treated with DMXAA alone. We also tested pentoxifylline and found it to suppress TNF production in response to DMXAA and to potentiate the anti-tumour effect of DMXAA. The results are compatible with the hypothesis that pharmacological reduction of serum TNF levels might benefit the anti-tumour effects of DMXAA and suggest new strategies for therapy using this agent.

(PDF emailed within 1 workday: $29.90)

Accession: 008893096

Download citation: RISBibTeXText

PMID: 9703279


Related references

Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. Anticancer Research 18(6a): 4409-4413, 1999

Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. British Journal of Cancer 80(5-6): 716-723, 1999

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. British Journal of Cancer 72(2): 339-343, 1995

Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). British Journal of Cancer 76(12): 1586-1591, 1997

Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor. Cancer ChemoTherapy and Pharmacology 53(5): 377-383, 2004

Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours. Cancer ChemoTherapy and Pharmacology 35(2): 153-160, 1994

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. British Journal of Cancer 78(4): 439-445, 1998

Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer ChemoTherapy and Pharmacology 36(2): 143-148, 1995

Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?. Acta Dermato-Venereologica 89(6): 601-603, 2010

Identification and reactivity of the major metabolite of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in humans. Xenobiotica 31(5): 277-293, 2001

Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency. British Journal of Cancer 74(7): 1090-1095, 1996

Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. International Journal of Hyperthermia 17(6): 508-519, November-December, 2001

Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice. Journal of Chromatography B 776(2): 231-236, 5 September, 2002

The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor. European Journal of Cancer 37(15): 1930-1937, 2001

Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 31(5): 277-293, 2001